Defibrotide 200Mg/2.5Ml Vialrecall:

—

Anticipated · Australia

Anticipated · 🇦🇺 Australia

Anticipated shortage

Reading today’s signals…

• Can I substitute?

No pathway on record

prescriber decision required

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Defibrotide 200Mg/2.5Ml Vialrecall:
Therapeutic category	Auto-created by TGA — Product Recalls (Australia) scraper
Controlled substance	No

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Recalls official enforcement reports

🇦🇺

Defibrotide 200mg/2.5mL vialRecall:

Pro Pharmaceuticals Group Pty Ltd · Apr 2020

Class Idetails ↗

🇦🇺

Defibrotide 200mg/2.5mL vialRecall:

Link Medical Products Pty Ltd T/A Link Pharmaceuticals · Apr 2020

Class Idetails ↗

🇦🇺

Defibrotide 200mg/2.5mL vialRecall:

Medsurge Healthcare Pty Ltd · Apr 2020

Class Idetails ↗

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.